Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Obstetrics/Gynecology (Women’s Health) | Family Medicine
Disease Category: Breast Cancer
Location: United States, CA
64 Cu-DOTA-Trastuzumab Positron Emission Tomography in Women with Advanced HER2 Positive Invasive Breast Cancer
You have been asked to participate in this research study because you have advanced breast cancer. The purpose of this research study is to develop the investigational agent 64Cu-DOTA-trastuzumab to image breast cancers that are HER2 positive. HER2 is a protein found in certain cancers, including breast cancer.
The study is conducted in two parts:
• In the first part we will enroll women whose cancers are known to be HER2 positive. The purpose is to give different doses of trastuzumab (Herceptin®) before giving 64Cu-DOTA-trastuzumab in order to test how we can obtain the clearest images.
• After the dose of trastuzumab to give before 64Cu-DOTA-trastuzumab has been determined, the second part of the study will enroll women whose cancers have varying amounts of HER2. The purpose is to test whether 64Cu-DOTA-trastuzumab can identify HER2 in breast cancers that are considered by the pathologist to be HER2 negative.
Your participation in this study is expected to last for one year.
Patient Inclusion/Exclusion Criteria:
- See http://clinicaltrials.coh.org for additional information.
City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)
Research Center Information: City of Hope
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these